The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution   Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)     Benjamin Garmezy Consulting or Advisory Role - Abbvie (Inst); Adaptimmune (Inst); Adicent Therapeutics (Inst); AIQ Global (Inst); Amgen (Inst); Arcus Biosciences (Inst); Arvinas (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); EMD Serono (Inst); Exelixis (Inst); Genentech/Roche (Inst); Janssen (Inst); Merck (Inst); Monte Rosa Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Rondo Therapeutics (Inst); Seagen (Inst); Specialty Networks (Inst); Takeda (Inst); Xencor (Inst) Research Funding - Abbvie (Inst); Accutar Biotech (Inst); Adcentrx Therapeutics (Inst); Adicet Therapeutics (Inst); Amgen (Inst); Arcus Biosciences (Inst); Arvinas (Inst); AstraZeneca (Inst); Avenzo Therapeutics (Inst); AVEO (Inst); Bicycle Therapeutics (Inst); crispr therapeutics (Inst); Eikon Therapuetics (Inst); Envision Pharma Group (Inst); Exelixis (Inst); Flare Therapeutics (Inst); Halda Therapeutics (Inst); Harbour BioMed (Inst); HiberCell (Inst); IDEAYA Biosciences (Inst); Janssen Oncology (Inst); Janux Therapeutics (Inst); Jubilant Therapeutics (Inst); Kineta (Inst); Kinnate Biopharma (Inst); Loxo (Inst); Merck (Inst); MiNK Therapeutics (Inst); Novartis (Inst); Nuvation Bio (Inst); Pfizer (Inst); ProfoundBio (Inst); Roche/Genentech (Inst); Takeda (Inst); Teon Therapeutics (Inst); Tmunity Therapeutics, Inc. (Inst); Xencor (Inst); Zenshine (Inst)   Arlene Siefker-Radtke Consulting or Advisory Role - Abbvie; Astellas Pharma; Bicycle Therapeutics; Biohaven Pharmaceuticals; EMD Serono; G1 Therapeutics; Gilead Sciences; Immunomedics; Janssen; Loxo; Merck; NCCN; Pfizer; Seagen; Taiho Pharmaceutical Research Funding - Bicycle Therapeutics (Inst); Janssen (Inst); Loxo (Inst); Merck (Inst); NIH (Inst) Patents, Royalties, Other Intellectual Property - Methods of characterizing and treating molecular subsets of muscle-invasive bladder cancer.   Andrae Vandross Employment - Next Oncology; Texas Oncology Consulting or Advisory Role - Abbvie (Inst); Boxer Capital (Inst); NiKang Therapeutics (Inst); Pliant Pharma Research Funding - Abbvie (Inst); Ascentage Pharma (Inst); BiOneCure (Inst); Bolt Biotherapeutics (Inst); Chugai Pharma (Inst); Deciphera (Inst); Exelixis (Inst); Gilead Sciences (Inst); Immunomedics (Inst); IMPAC Medical Systems (Inst); Kirilys Therapeutics (Inst); Kura Oncology (Inst); Lyvgen Biopharma (Inst); MBRACE (Inst); Medikine (Inst); Nanjing (Inst); Nested Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Nitto BioPharma (Inst); OncoResponse (Inst); Pliant (Inst); PMV Pharma (Inst); Sirnaomics (Inst); Tachyon Therapeutics (Inst); Teon Therapeutics (Inst); Vividion Therapeutics (Inst); Xilio Therapeutics (Inst); Yufan Biotechnologies (Inst); ZielBio (Inst); Zumutor Biologics (Inst)   Cesar Perez Consulting or Advisory Role - BeiGene; Ipsen; Pfizer Research Funding - Accutar Biotech (Inst); ADANATE Biotechnology (Inst); Avenzo Therapeutics (Inst); Avenzo Therapeutics (Inst); BeiGene (Inst); Coherent Biopharma (Inst); Coherus Biosciences (Inst); Compass Therapeutics (Inst); Corvus Pharmaceuticals (Inst); DualityBio (Inst); Elevation Oncology (Inst); Exelixis (Inst); Genentech (Inst); Kura Oncology (Inst); Loxo/Lilly (Inst); Menarini (Inst); Merus (Inst); Mirati Therapeutics (Inst); NextCure (Inst); PDS Biotechnology (Inst); Pfizer (Inst); Pierre Fabre (Inst); Relay Therapeutics (Inst); Systimmune (Inst); Tachyon Therapeutics (Inst); Tallac Therapeutics (Inst); Torl Biotherapeutics (Inst); Xilio Therapeutics (Inst); Zhuhai Yufan Biotechnologies (Inst)   Neal Shore Stock and Other Ownership Interests - Photocure Consulting or Advisory Role - Accord Research; Alessa Therapeutics; Amgen; Antev; Asieris Pharmaceuticals; Astellas Pharma; AstraZeneca; Aura Biosciences; Bayer; Bioprotect; Bristol-Myers Squibb/Sanofi; CG Oncology; Clarity Pharmaceuticals; Dendreon; Exact Imaging; Ferring; Fize Medical; Glytherix; ImmunityBio; InVitae; Janssen Scientific Affairs; Lantheus Medical Imaging; Lilly; MDxHealth; Medivation/Astellas; Merck; Minomic; Myriad Genetics; Novartis; Nusano; Pfizer; Photocure; PlatformQ Health; Promaxo; Protara Therapeutics; Sanofi; Siemens; Speciality Networks; Sumitomo Pharma Oncology; Telix Pharmaceuticals; Tolmar; Tutelix; Urogen pharma Research Funding - Abbvie; Advantagene; Amgen; Aragon Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb/Pfizer; CG Oncology; Clovis Oncology; Dendreon; DisperSol; Endocyte; Exact Imaging; Exelixis; Ferring; FKD Therapies; FORMA Therapeutics; Foundation Medicine; Genentech; Guardant Health; InVitae; Istari Oncology; Janssen; Jiangsu Yahong Meditech; MDxHealth; Medivation; Merck; MT Group; Myovant Sciences; Myriad Genetics; Novartis; Nymox; OncoCellMDx; ORIC Pharmaceuticals; pacific edge; Palette Life Sciences; Pfizer; Plexxikon; POINT Biopharma; Propella Therapeutics; Propella Therapeutics; RhoVac; Sanofi; SeaGen; Sesen Bio; Steba Biotech; Theralase; Tolmar; Urogen pharma; Urotronic; US Biotest; Vaxiion; Veru; Zenflow   Daniel Petrylak Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bicycle Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Gilead Sciences; Incyte; Ipsen; Janssen; Lilly; Mirati Therapeutics; Monopteros Therapeutics; Pfizer; Pharmacyclics; Regeneron; Roche; Seagen; Urogen pharma Research Funding - Advanced Accelerator Applications (Inst); Agensys (Inst); Astellas Medivation (Inst); AstraZeneca (Inst); Bayer (Inst); BioXCel therapeutics (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Eisai (Inst); Endocyte (Inst); Genentech (Inst); Gilead Sciences (Inst); Innocrin Pharma (Inst); Lilly (Inst); MedImmune (Inst); Medivation (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Progenics (Inst); Replimune (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst) Expert Testimony - Celgene; sanofi   Mohammad Hirmand Employment - Avenzo Therapeutics Leadership - Atavistik Bio; Avenzo Therapeutics; Whitehawk Therapeutics Stock and Other Ownership Interests - Avenzo Therapeutics   Minal Mehta Employment - Avenzo therapeutics Stock and Other Ownership Interests - Avenzo therapeutics   Vadim Koshkin Consulting or Advisory Role - Astellas Pharma; Bicycle Therapeutics; Bristol Myers Squibb Foundation; Janssen; Loxo; Merck; MSD; Natera; Pfizer; Roche/Genentech; Tempus Research Funding - Curium Pharma (Inst); Gilead Sciences (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Pfizer/Astellas (Inst); Seagen (Inst); Taiho Oncology (Inst); Tyra Biosciences (Inst) Travel, Accommodations, Expenses - Astellas Pharma; Pfizer